Ann Rheum Dis: Florbetapir[18F]正电子发射断层扫描:包涵体肌炎中肌肉淀粉样蛋白的识别及与多发性肌炎的鉴别

2019-02-16 xiangting MedSci原创

florbetapir[18F]淀粉样蛋白正电子发射断层扫描可以区分IBM与PM。

使用目前可用的工具来确诊包涵体肌炎(IBM)存在困难。许多患者最初被误诊为多发性肌炎(PM)。这项在英国成人神经肌肉中心进行的观察性研究探讨了淀粉样蛋白正电子发射断层扫描是否可以区分IBM和PM。

10例IBM患者和6例PM患者接受florbetapir[18F]正电子发射断层扫描和骨骼肌肉组织MRI。评估了感兴趣的骨骼肌区域florbetapir[18F] 标准化摄取值比率的差异。评估了florbetapir[18F]标准化摄取值比率与疾病严重程度指标(临床和骨骼肌MRI)之间的关联。

与PM相比,IBM患者所有评估区域的florbetapir[18F]标准化摄取值比率显著升高(总florbetapir[18F]标准化摄取值比率1.45(1.28至2.05)vs 1.01(0.80至1.22),p=0.005)。总florbetapir[18F]标准化摄取值比率≥1.28时,IBM的敏感性和特异性分别为80%和100%。

florbetapir[18F]淀粉样蛋白正电子发射断层扫描可以区分IBM与PM。成功利用该项检查有助于正确诊断临床试验的纳入,并避免潜在不必要的有害治疗。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-05-17 jml2009
  6. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1942733, encodeId=0a681942e33b3, content=<a href='/topic/show?id=fbfc3345060' target=_blank style='color:#2F92EE;'>#包涵体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33450, encryptionId=fbfc3345060, topicName=包涵体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu May 30 05:11:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012950, encodeId=d9ff2012950e2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 12 23:11:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761012, encodeId=92981e6101269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 11 07:11:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937381, encodeId=0b5d193e381c5, content=<a href='/topic/show?id=f95943110f7' target=_blank style='color:#2F92EE;'>#多发性肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43110, encryptionId=f95943110f7, topicName=多发性肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 26 11:11:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889983, encodeId=fff3188998329, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri May 17 10:11:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984581, encodeId=5c82198458187, content=<a href='/topic/show?id=789c3345242' target=_blank style='color:#2F92EE;'>#包涵体肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33452, encryptionId=789c3345242, topicName=包涵体肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Mon Jul 22 21:11:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442857, encodeId=378d144285e08, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Mon Feb 18 02:11:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]

相关资讯

Circulation:改善18F-FDG PET/CT对人工心脏瓣膜心内膜炎的诊断性能

FDG PET/CT的视觉和定量评估对疑似PVE患者具有很高的诊断准确性。

Arthritis Rheumatol:正电子发射断层扫描作为大血管炎的影像学生物标志物

FDG-PET提供有关血管炎症的信息,这些信息与LVV的临床评估是相辅相成的。

JCO:磁共振成像和[18F]氟脱氧葡萄糖正电子发射断层扫描在有症状多发性骨髓瘤患者的诊断与维持治疗前的前瞻性评估研究:IMAJEM研究结果

众所周知磁共振成像(MRI)和正电子发射断层扫描(PET-CT)是多发性骨髓瘤(MM)患者重要的检查手段。2017年7月在JCO上发表的一篇文章对MM患者进行了一项前瞻性研究,目的是比较MRI和PET-CT对骨损伤的诊断及这些技术的预后价值。

Ann Rheum Dis:大血管炎中MR血管造影与18F-氟脱氧葡萄糖正电子发射断层扫描的比较

在评估LVV时,MRA和PET可以提供独特和补充信息。MRA更好地捕捉疾病程度,PET扫描更适合评估血管活动性。